Drug Trial Radar · NCT06492070
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Aug 1, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for patients with gynecologic cancers. Peripheral neuropathy is a common side effect of many chemotherapeutic agents, including paclitaxel. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Cryocompression is a therapy that combines compression garments or dressings with cooling of the treated area. Cilostazol is in a class of medications called platelet-aggregation inhibitors (antiplatelet medications). It works by improving blood flow to the legs. Giving cilostazol together with cryocompression may be safe and tolerable in treating patients with gynecological cancers.
Conditions
- Cervical Carcinoma
- Fallopian Tube Carcinoma
- Malignant Solid Neoplasm
- Malignant Uterine Neoplasm
- Ovarian Carcinoma
- Primary Peritoneal Carcinoma
- Vulvar Carcinoma
Interventions
Best PracticeOther
Undergo standard of care
CilostazolDrug
Given PO
Cryocompression TherapyDevice
Undergo cryocompression therapy
PaclitaxelDrug
Given by infusion
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in sensation and vibration objective neuropathy scores (Arms A and B)Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months
- Rates of impaired sensation and vibration on objective neuropathy testing and ≥ Grade 2 neuropathy among patients who recently completed paclitaxel treatment with standard of care treatment protocols (Arm C)Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Not yet recruiting
Emory Saint Joseph's Hospital
Atlanta, Georgia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.